All Press Releases for June 11, 2024

Kishore Kumar Hotha, PhD, MBA, has been Inducted into the Prestigious Marquis Who's Who Biographical Registry

Kishore Kumar Hotha, PhD, MBA, recognized for pioneering innovations in research and development for over two decades.

Dr. Kishore Hotha is a technical leader at Veranova, serving as the Global Vice President of Analytical Research and development (AR&D) laboratory operations.

    AYER, MA, June 11, 2024 /24-7PressRelease/ -- Kishore Kumar Hotha, PhD, MBA, has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected based on current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are considered during selection.

Dr. Hotha is a prominent scientific leader in the pharmaceutical industry, with over twenty years of experience across the pharmaceutical, biotech, and Contract Development and Manufacturing Organization (CDMO) sectors. He has played a pivotal role in developing scientific and business strategies for numerous Investigational New Drug (IND) applications, New Drug Applications (NDAs), and Abbreviated New Drug Applications (ANDAs), guiding them from concept through to commercialization.

Dr. Kishore Hotha is a technical leader at Veranova, serving as the Global Vice President of Analytical Research and development (AR&D) laboratory operations. Prior to his current position, Dr. Hotha served as global director of lab operations at Johnson Matthey from 2020 to 2022. Before that, he was the head of AR&D and QC lab operations at Lupin between 2012 and 2020. Dr. Hotha's earlier roles include deputy manager of analytical and bioanalytical QC lab operations at Dr. Reddy's Laboratories Ltd. from 2006 until 2012 and research associate in AR&D at Cadila Pharmaceuticals and Aurobindo Pharma from 2003 to 2006.

Dr. Hotha's contributions transcend his professional engagements. His active involvement as an advisory board member for the International Journal of Innovative and Applied Research and an academic editor for the British Journal of Medicine and Medical Research has significantly enriched the academic and scientific community, earning him widespread respect and admiration.

In addition to his career, Dr. Hotha has pursued higher education and accreditation to hone his expertise further. He earned a PhD in analytical chemistry from JNTU Anantapur in 2012, followed by a Master of Business Administration at Southern New Hampshire University in 2024. Additionally, he holds a certification as a Green Belt in operational excellence and lab operations from BMGI as of 2019, underscoring his dedication to excellence and continuous improvement of laboratory functionality.

Dr. Hotha has substantially advanced pharmaceutical research and development, authoring over 50 scholarly articles and frequently serving as a keynote speaker at prestigious conferences. Notably, he delivered insightful presentations at the CPHi conference in May 2024 on the critical challenges associated with the development, manufacturing, supply chain, and safety of Antibody Drug Conjugates. At the ADC Analytical Summit in April 2024, he discussed strategic approaches to the fast-to-clinic process, emphasizing ways to accelerate scientific biotech innovations for quicker delivery of medicines to the market, thus benefiting patients and the scientific community. His works include strategic research and development on small-molecule drug substances and drug products, antibody-drug conjugates, Oligonucleotides, and peptides in new pharmaceutical eras, as well as the role of contract development and manufacturing organizations in innovation.

Dr. Hotha's most recent works include an article published in Chemistry Today titled "Realizing the Potential of Antibody-Drug Conjugates," where he discusses advanced methods to enhance the safety and efficacy of antibody-drug conjugates. During a Chemistry Today panel discussion, he also contributed his expertise on using artificial intelligence (AI) in pharmaceutical supply chains, focusing on navigating the challenges of data-driven transformations in the sector. Dr. Hotha has also authored in-depth research articles on technology transfers, concept to commercialization, power of innovation through leadership in CDMOs, and thorough analyses of drug excipient interactions and drug degradation pathways. These contributions have provided valuable insights and case studies to several pharmaceutical and biotechnological companies, significantly aiding in advancing drug development and manufacturing processes.

Dr. Hotha is dedicated to advancing his role as a distinguished research professional in the pharmaceutical industry. He specializes in drug substance and drug product development, focusing on small molecules, oncology, oligonucleotides, and peptides, among other areas. He dedicates himself to exploring numerous leadership talks, writing technical content, and assisting scientific and personal communities in his free time. This blend of professional ambition and personal dedication showcases Dr. Hotha's unwavering commitment to excellence in his field and the community.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website,

# # #

Contact Information

-- --
Marquis Who's Who Ventures LLC
Uniondale, NY
Voice: 844-394-6946
E-Mail: Email Us Here
Website: Visit Our Website
Follow Us: